Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
Healthcare
$3.06 -1.03%
-$0.06 today
- Market cap
- $769.20M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
52W Low $3.49High $8.40
Volume 3.39M
Average 3.58M
Income Statement
Follow revenue through to earnings.
Revenue
$407.32M
FY 2025 · Annual
+22.1% YoYOperating Income
-$40.98M
FY 2025 · Annual
Net Income
-$61.60M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.1M | 52.16M | 124.46M | 333.62M | 407.32M |
| Cost of Revenue | 1M | 4.12M | 17.8M | 50.56M | 42.6M |
| Gross Profit | 9.1M | 48.04M | 106.66M | 283.06M | 364.72M |
| Gross Margin | 90.1% | 92.1% | 85.7% | 84.8% | 89.5% |
| Research & Development | 91.14M | 35.2M | 35.54M | 52.32M | 68.47M |
| Selling, General & Admin | 72.3M | 76.6M | 134.4M | 258.69M | 337.23M |
| Operating Expenses | 163.44M | 111.8M | 169.94M | 311.01M | 405.7M |
| Depreciation & Amortization | 2.81M | 1.14M | 1.29M | 2.06M | 3.06M |
| EBITDA | (150.85M) | (60.98M) | (55.35M) | (16.71M) | (29.17M) |
| EBITDA Margin | -1494.0% | -116.9% | -44.5% | -5.0% | -7.2% |
| Operating Income | (154.35M) | (63.76M) | (63.28M) | (27.95M) | (40.98M) |
| Operating Margin | -1528.6% | -122.2% | -50.8% | -8.4% | -10.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.5M | 5.07M | 8.87M | 20.09M | 28.4M |
| Other Income / Expenses | (3.82M) | (3.44M) | (2.24M) | (10.92M) | (19.65M) |
| Income Before Tax | (158.16M) | (67.2M) | (65.52M) | (38.87M) | (60.63M) |
| Pre-Tax Margin | -1566.4% | -128.8% | -52.6% | -11.7% | -14.9% |
| Income Tax Expense | 4K | 8K | 547K | 266K | 969K |
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Net Margin | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
| EPS (Basic) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| EPS (Diluted) | (1.52) | (0.42) | (0.30) | (0.17) | (0.26) |
| 104.21M | 158.69M | 219.33M | 235.23M | 241.03M | |
| 104.21M | 158.69M | 219.33M | 235.23M | 241.03M |
ARDX Earnings Waterfall · TTM
NASDAQ:ARDX · Revenue to Net Income
Key Ratios
EPS$-0.24
Gross Margin91.9%
Net Margin-15.1%
P/E Ratio-309.6
P/S Ratio12.2
Analysis
$427.7M of revenue converted into -$58.1M of net income for the selected period. Gross margin is 91.9% and net margin is -15.1%, showing how much revenue survives after costs and taxes. EPS is $-0.24, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 25, 2026 |
How much revenue does ARDX generate?
Ardelyx, Inc. (ARDX) reported $407.32M of revenue in fiscal 2025.
Is ARDX profitable?
Ardelyx, Inc. (ARDX) reported -$61.60M of net income, with a net margin of -15.1%.
Continue the stock analysis
Jump to another research area for this company.